MEHMET OKCU to Cerebellar Neoplasms
This is a "connection" page, showing publications MEHMET OKCU has written about Cerebellar Neoplasms.
Connection Strength
2.864
-
Scoliosis in Children Treated With Photon Craniospinal Irradiation for Medulloblastoma. Int J Radiat Oncol Biol Phys. 2021 03 01; 109(3):712-717.
Score: 0.511
-
Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma. Pediatr Blood Cancer. 2013 Apr; 60(4):593-8.
Score: 0.286
-
Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro Oncol. 2009 Jun; 11(3):292-300.
Score: 0.217
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
Score: 0.164
-
Adaptive, behavioral, and emotional outcomes following postoperative pediatric cerebellar mutism syndrome in survivors treated for medulloblastoma. J Neurosurg Pediatr. 2024 06 01; 33(6):516-523.
Score: 0.158
-
Proton Therapy Mediates Dose Reductions to Brain Structures Associated With Cognition in Children With Medulloblastoma. Int J Radiat Oncol Biol Phys. 2024 May 01; 119(1):200-207.
Score: 0.154
-
Cerebellar Mutism Syndrome in Pediatric Neuro-oncology: A Multidisciplinary Perspective and Call for Research Priorities. Pediatr Neurol. 2022 07; 132:4-10.
Score: 0.139
-
Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma. J Neurooncol. 2021 Oct; 155(1):93-100.
Score: 0.133
-
Overall survival and secondary malignant neoplasms in children receiving passively scattered proton or photon craniospinal irradiation for medulloblastoma. Cancer. 2021 Oct 15; 127(20):3865-3871.
Score: 0.131
-
Reply to S.A. Milgrom et al. J Clin Oncol. 2020 07 01; 38(19):2212-2213.
Score: 0.121
-
Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. J Clin Oncol. 2020 02 10; 38(5):454-461.
Score: 0.117
-
Pilot study of DNA methylation-derived neutrophil-to-lymphocyte ratio and survival in pediatric medulloblastoma. Cancer Epidemiol. 2019 04; 59:71-74.
Score: 0.110
-
DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors. Neuro Oncol. 2017 Oct 01; 19(10):1372-1379.
Score: 0.101
-
Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients. Cancer Epidemiol. 2016 10; 44:161-166.
Score: 0.094
-
SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma. Cancer Med. 2015 Nov; 4(11):1679-86.
Score: 0.088
-
Antioxidant enzyme polymorphisms and neuropsychological outcomes in medulloblastoma survivors: a report from the Childhood Cancer Survivor Study. Neuro Oncol. 2012 Aug; 14(8):1018-25.
Score: 0.070
-
An exploratory case-only analysis of gene-hazardous air pollutant interactions and the risk of childhood medulloblastoma. Pediatr Blood Cancer. 2012 Oct; 59(4):605-10.
Score: 0.068
-
Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer. 2011 Feb 01; 117(3):635-41.
Score: 0.062
-
Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1445-50.
Score: 0.060
-
Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma. Clin Cancer Res. 2010 Feb 01; 16(3):1049-57.
Score: 0.059
-
Consensus Report From the Stockholm Pediatric Proton Therapy Conference. Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):387-392.
Score: 0.024